Drug Classes & How They Work

  • The four approved DPP-4 inhibitors share a common incretin-preserving mechanism and similar A1c efficacy (~0.5% to 0.8% reduction), but differ markedly in their routes of elimination (renal excretion versus hepatobiliary excretion) and heart failure safety profiles (1.1) (2.1) (4.1).
Active Ingredient & Brand Standard Adult Dose Renal Dose Adjustments (by eGFR) Elimination Route & Clinical Distinctions
Sitagliptin (Januvia) 100 mg once daily (with or without food) 50 mg once daily if eGFR 30 to <45 mL/min; 25 mg once daily if eGFR <30 mL/min or ESKD on dialysis ~80% excreted unchanged in urine; neutral heart failure risk demonstrated in TECOS cardiovascular outcome trial (1.1) (2.1)
Linagliptin (Tradjenta / Canadian Trajenta) 5 mg once daily (with or without food) No renal dose adjustment required at any eGFR (including severe CKD and hemodialysis) ~80%-90% eliminated via enterohepatic biliary/fecal route; preferred DPP-4 inhibitor in fluctuating or severe renal impairment (CARMELINA trial) (1.1) (2.1) (3.1)
Saxagliptin (Onglyza) 5 mg once daily (with or without food) 2.5 mg once daily if eGFR <45 mL/min or when co-administered with strong CYP3A4/5 inhibitors Metabolized via CYP3A4/5 and excreted renally; avoid in patients with heart failure history (SAVOR-TIMI 53 signal) (2.1) (4.1)
Alogliptin (Nesina) 25 mg once daily (with or without food) 12.5 mg once daily if eGFR 30 to <60 mL/min; 6.25 mg once daily if eGFR <30 mL/min Primarily renal excretion; use caution in patients with heart failure or renal impairment (2.1) (4.1)

DPP-4 inhibitors: Clinical Overview & Scope

  • Dipeptidyl peptidase-4 (DPP-4) inhibitors, known pharmacologically as "gliptins", are oral antihyperglycemic agents that selectively inhibit the cell-surface and circulating DPP-4 enzyme responsible for rapidly degrading endogenous incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) (1.1) (2.1).

  • By extending the physiological half-life of active meal-stimulated GLP-1 and GIP roughly two- to threefold, DPP-4 inhibitors enhance pancreatic beta-cell insulin synthesis and secretion and suppress alpha-cell glucagon release strictly in a glucose-dependent manner (1.1) (3.1).

  • Because their insulinotropic effect switches off as blood glucose returns to normal fasting levels, DPP-4 inhibitors are weight-neutral and carry a very low intrinsic risk of hypoglycemia when used as monotherapy or combined with metformin or SGLT2 inhibitors (1.1) (2.1).

  • Representative medications in our dpp-4 inhibitors directory include Januvia (Sitagliptin Phosphate), Galvus (Vildagliptin), Nesina (Alogliptin), Onglyza (Saxagliptin), Saxagliptin (Generic), Trajenta (Linagliptin) (1.1).

Dosage Forms, Release Profiles & Devices

  • All DPP-4 inhibitors are formulated as once-daily oral tablets that can be taken at any consistent time of day with or without food (2.1).
  • Notice how renal elimination shapes tablet strength selection: whereas sitagliptin (Januvia 100 mg, 50 mg, 25 mg), saxagliptin (Onglyza 5 mg, 2.5 mg), and alogliptin (Nesina 25 mg, 12.5 mg, 6.25 mg) are manufactured in three or two renal-tiered strengths requiring periodic eGFR verification, linagliptin (marketed as Tradjenta in the U.S. and Trajenta in Canada) is manufactured in a single 5 mg strength that requires no dose adjustment across all stages of chronic kidney disease (1.1) (2.1) (3.1).

Key Safety, Storage & Monitoring Points

  • DPP-4 inhibitors must not be co-administered with GLP-1 receptor agonists (such as semaglutide, liraglutide, dulaglutide, or tirzepatide), as combining an endogenous incretin degradation blocker with a pharmacological incretin receptor agonist provides no clinically meaningful additive glycemic benefit while increasing cost and side-effect exposure (1.1).
  • Across the DPP-4 class, prescribing labels include warnings for acute pancreatitis (patients should discontinue therapy immediately and seek medical evaluation if persistent, severe abdominal pain radiating to the back occurs), severe and disabling arthralgia (joint pain that resolves upon drug discontinuation), and bullous pemphigoid (a rare blistering skin condition requiring dermatologic evaluation) (2.1) (4.1).
  • When a DPP-4 inhibitor is added to an existing sulfonylurea (such as glimepiride or glipizide) or basal insulin regimen, a dose reduction of the sulfonylurea or insulin may be required to prevent hypoglycemia (1.1) (2.1).

Ordering & Prescription Checklist for U.S. Patients

  • Match your prescription details: Confirm the active ingredient name, exact milligram or microgram strength, release profile, and package quantity on your U.S. prescription (2.1) (4.1).
  • Licensed pharmacist review: Every order undergoes a dosing, strength, and drug-interaction check in under 1 business day, followed by a mandatory pharmacist consultation before dispatch (3.1).
  • Transparent USD pricing and shipping: Room-temperature medications ship for $14.99 USD flat rate and cold-chain medications ship in $29.99 USD insulated coolers via tracked Canada Post and USPS delivery.
  • Need help matching a product or transferring an Rx? Call 1-888-868-1920 (Monday - Friday: 9:00AM - 6:00PM; Saturday - Sunday: Closed) or review our step-by-step ordering guide and prescription requirements.

Frequently Asked Questions

Why does Tradjenta / Trajenta (linagliptin) only come in one 5 mg strength while Januvia comes in 25 mg, 50 mg, and 100 mg?

Unlike Januvia (sitagliptin), which is cleared ~80% by the kidneys and requires lower milligram doses (50 mg or 25 mg) when kidney function declines, linagliptin is cleared primarily through the liver and bile into the stool (<5% renal excretion) (1.1) (2.1). Therefore, the same 5 mg once-daily dose of linagliptin is safe and effective regardless of kidney function.

Should I stop taking Januvia or Tradjenta if my doctor starts me on Ozempic or Mounjaro?

Yes. Clinical guidelines from the American Diabetes Association state that DPP-4 inhibitors should be discontinued when a GLP-1 or dual GIP/GLP-1 receptor agonist is initiated, because both drug classes act on the same GLP-1 incretin pathway (1.1).

Why do saxagliptin (Onglyza) and alogliptin (Nesina) have heart failure precautions that sitagliptin and linagliptin do not share to the same degree?

In the SAVOR-TIMI 53 cardiovascular outcome trial, saxagliptin showed a small but statistically significant increase in hospitalization for heart failure (particularly in patients with preexisting heart failure or kidney disease), whereas sitagliptin (TECOS) and linagliptin (CARMELINA) demonstrated neutral heart failure hospitalization rates matching placebo (1.1) (2.1) (4.1).

Related Practical Comparison Guides

References & Official Clinical Sources

Pharmacological classifications, mechanism comparisons, dosing-form distinctions, and clinical safety notes for dpp-4 inhibitors are compiled from official regulatory prescribing monographs and medical practice guidelines:

Need help finding your medication? Call 1-888-868-1920.

Call 1-888-868-1920Help